Cargando…
A real-world analysis on the efficacy and tolerability of liposomal irinotecan plus 5-fluorouracil and folinic acid in metastatic pancreatic ductal adenocarcinoma in Belgium
BACKGROUND: Currently, nanoliposomal irinotecan (nal-IRI) + 5-fluorouracil/folinic acid (5-FU/LV) is the only approved second-line treatment for patients suffering from metastatic pancreatic ductal adenocarcinoma (mPDAC). However, also other chemotherapeutic regimens are used in this setting and due...
Autores principales: | Verbruggen, Lise, Verheggen, Lisa, Vanhoutte, Greetje, Loly, Catherine, Lybaert, Willem, Borbath, Ivan, Vergauwe, Philippe, Hendrickx, Koen, Debeuckelaere, Celine, de Haar-Holleman, Amy, Van Laethem, Jean-Luc, Peeters, Marc |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10439761/ https://www.ncbi.nlm.nih.gov/pubmed/37600936 http://dx.doi.org/10.1177/17588359231181500 |
Ejemplares similares
-
A real-world analysis of second-line treatment options in pancreatic cancer: liposomal-irinotecan plus 5-fluorouracil and folinic acid
por: Kieler, Markus, et al.
Publicado: (2019) -
Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study
por: Raoul, Jean-Luc, et al.
Publicado: (2009) -
Ternary combination of irinotecan, fluorouracil-folinic acid and oxaliplatin: results on human colon cancer cell lines
por: Fischel, J-L, et al.
Publicado: (2001) -
Posterior reversible encephalopathy syndrome while receiving irinotecan with fluorouracil and folinic acid for metastatic gastric cancer
por: Abughanimeh, Omar K, et al.
Publicado: (2017) -
First evidence for the antitumor activity of nanoliposomal irinotecan with 5-fluorouracil and folinic acid in metastatic biliary tract cancer
por: Taghizadeh, Hossein, et al.
Publicado: (2020)